Jun 2026 (Q2 FY26) — Jul 28, 2026
Alkermes Q2 FY26 — Orexin Platform Leadership and Commercial Strength
Read the full callAlkermes (ALKS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Alkermes earnings: last reported Tue, 28 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 496 | +27.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.7 | −20.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.50 | −99.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
34 of 40 judged targets kept · 46 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $100 million to $120 million | Mar 2026 | Adjusted EBITDA was $139.2 million, which we believe is more representative of cash generated by the business during the quarter. | Achieved |
| Cost of goods sold | $85 million to $95 million | Mar 2026 | Cost of goods sold in the second quarter were $98.1 million, which includes the purchase price fair value accounting of LUMRYZ inventory that we described last quarter. | Missed |
| EBITDA | $60 million to $90 million | Dec 2025 | We now expect GAAP net loss in the range of $95 million to $115 million and positive EBITDA in the range of $75 million to $95 million. | Revised Down |
6 of Alkermes plc.'s 86 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 83 more targets are in the full ledger.
Claimed
- Proprietary product net sales increased 34% year-over-year to $411.7 million.
- LYBALVI access expanded to cover over 80% of insured lives, including major Part D plans.
- LUMRYZ generated net sales of $96.6 million in its first full quarter post-acquisition, with 3,900 patients on therapy.
- VIVITROL agreement with Amneal terminated, confirming no authorized generic in 2027.
- Positive Phase 3 results for LUMRYZ in idiopathic hypersomnia (IH), enabling sNDA submission by year-end.
Qualified
- LYBALVI gross-to-net adjustments are expected to expand in the second half of the year, reaching the high 30s for the full year.
- Q3 total revenues are expected to be lower than Q2, in the range of $450 million to $470 million, partly due to reduced CONSTA revenue and LUMRYZ inventory timing.
Price
$40.1 +2.61% · +$1.02
Performance +25.5% 1Y
1Y: $31.94 on 14 Oct 2025 → $40.1. High $55.22 (7 Jul 2026), low $27.2 (18 Mar 2026).
- Previous close
- $39.08
- 52-week range
- $27.2 – $55.22
- One year
- +24.42%
Overview
- Symbol
- ALKS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
34 of 40 judged targets kept · 46 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $100 million to $120 million | Mar 2026 | Adjusted EBITDA was $139.2 million, which we believe is more representative of cash generated by the business during the quarter. | Achieved |
| Cost of goods sold | $85 million to $95 million | Mar 2026 | Cost of goods sold in the second quarter were $98.1 million, which includes the purchase price fair value accounting of LUMRYZ inventory that we described last quarter. | Missed |
| EBITDA | $60 million to $90 million | Dec 2025 | We now expect GAAP net loss in the range of $95 million to $115 million and positive EBITDA in the range of $75 million to $95 million. | Revised Down |
Claimed
- Proprietary product net sales increased 34% year-over-year to $411.7 million.
- LYBALVI access expanded to cover over 80% of insured lives, including major Part D plans.
- LUMRYZ generated net sales of $96.6 million in its first full quarter post-acquisition, with 3,900 patients on therapy.
- VIVITROL agreement with Amneal terminated, confirming no authorized generic in 2027.
- Positive Phase 3 results for LUMRYZ in idiopathic hypersomnia (IH), enabling sNDA submission by year-end.
Qualified
- LYBALVI gross-to-net adjustments are expected to expand in the second half of the year, reaching the high 30s for the full year.
- Q3 total revenues are expected to be lower than Q2, in the range of $450 million to $470 million, partly due to reduced CONSTA revenue and LUMRYZ inventory timing.
The full ledger
Open Alkermes plc.’s full ledger
A free account opens 5 company ledgers a month. All 86 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Alkermes Q1 FY26 — Strong Commercial Performance and Strategic Acquisition
Read the full callDec 2025 (Q4 FY25) — Feb 25, 2026
Alkermes Q4 FY25 — Strong Commercial Performance and Orexin Pipeline Advancement
Read the full callEvery analysed call
Alkermes earnings calls (ALKS)
Financials
What the filings say
Net profit, year on year: −99% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 430 | 307 | 391 | 394 | 385 | 393 | 496 |
| Expenses | 273 | 267 | 293 | 298 | 305 | 326 | 441 | 478 |
| Operating profit | 105 | 163 | 14 | 93 | 89 | 58 | -48 | 18 |
| Operating margin | 27.7% | 37.8% | 4.5% | 23.8% | 22.6% | 15.1% | −12.3% | 3.7% |
| Other income | 5 | 7 | 12 | 12 | 12 | 2 | -14 | -20 |
| Interest | 6 | 5 | 0 | 0 | 0 | 12 | 21 | 26 |
| Profit before tax | 110 | 170 | 25 | 105 | 101 | 60 | -62 | -2 |
| Tax rate | 15.8% | 14.2% | 11.9% | 16.9% | 17.9% | 18.3% | −7.3% | 126.7% |
| Net profit | 92 | 147 | 22 | 87 | 83 | 49 | -66 | 1 |
| EPS ($ per share) | 0.57 | — | 0.14 | 0.53 | 0.50 | — | -0.40 | 0 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | -1,185 | -1,382 | -1,493 | -1,541 | -1,699 | -1,344 | -976 | -735 |
| Total liabilities | 654 | 720 | 883 | 912 | 920 | 934 | 591 | 668 |
| Fixed assets | 310 | 362 | 350 | 341 | 223 | 227 | 228 | 222 |
| Investments | 273 | 331 | 362 | 199 | — | — | — | — |
| Total assets | 1,825 | 1,805 | 1,950 | 2,024 | 1,964 | 2,136 | 2,056 | 2,487 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 99 | 72 | 83 | 102 | 21 | 401 | 439 | 521 |
| Cash from investing | -22 | -142 | -11 | -66 | -65 | 53 | -111 | 295 |
| Cash from financing | -2 | 7 | -2 | 29 | -2 | -290 | -494 | 12 |
| Net cash flow | 75 | -63 | 69 | 65 | -45 | 165 | -166 | 829 |
| Capital expenditure | -69 | -91 | -42 | -28 | -38 | -48 | -33 | -40 |
| Free cash flow | 30 | -19 | 41 | 74 | -17 | 353 | 406 | 480 |
ALKS operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Patients LUMRYZ | ~3,500In 2025, LUMRYZ generated approximately $279 million in net sales, with approximately 3,500 patients on LUMRYZ therapy as of the end of 2025, a roughly 40% increase in number of patients from the fourth quarter of 2024.Source: earnings call transcript | ~3,600We exited the quarter with approximately 3,600 patients on therapy and with solid momentum in new patient enrollments, which we expect to build on as we move through the year.Source: earnings call transcript | ~3,900We exited the quarter with approximately 3,900 patients on therapy.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
120 filings between Nov 3, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$10.28M
33 sales by 7 insiders
94% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 5
- Award — granted as compensation
- 47
- Option exercise — converted options into shares
- 35
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hopkinson Craig C. | — | $3.66M | Sep 1, 2026 |
| snyderman nancy lynn MD | — | $2.24M | Aug 3, 2026 |
| Cooke Shane | — | $2.12M | Feb 2, 2026 |
| Parisi Samuel Joseph | — | $888.8K | May 29, 2026 |
| Gaffin David Joseph | — | $735.3K | Oct 2, 2026 |
| Nichols Christian Todd | — | $552.9K | Aug 17, 2026 |
| Wright Christopher I | — | $90.2K | Jun 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Reed Joshua SVP, Chief Financial Officer | Option exercise | 9,164 | — |
| Oct 8, 2026 | Reed Joshua SVP, Chief Financial Officer | Tax withheld | 4,069 | $163.2K |
| Oct 2, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $83.5K |
| Sep 3, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $97.7K |
| Sep 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 9,000 | $422.9K |
| Sep 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $123.0K |
| Aug 17, 2026 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 plan | 6,912 | $340.0K |
| Aug 17, 2026 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 plan | 664 | $33.0K |
| Aug 3, 2026 | snyderman nancy lynn MD Director | Option exercise | 27,948 | $1.31M |
| Aug 3, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 9,000 | $437.2K |
| Aug 3, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 104 | $2.0K |
| Aug 3, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $98.8K |
| Aug 3, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 4,896 | $120.4K |
| Aug 3, 2026 | snyderman nancy lynn MD Director | Sale | 44,472 | $2.24M |
| Aug 3, 2026 | snyderman nancy lynn MD Director | Option exercise | 16,524 | $772.0K |
| Jul 6, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $109.9K |
| Jul 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 8,300 | $427.1K |
| Jul 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $96.7K |
| Jul 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 700 | $36.5K |
| Jun 12, 2026 | Wright Christopher I Director | Sale 10b5-1 plan | 2,000 | $90.2K |
| Jun 4, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $87.6K |
| Jun 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 9,000 | $375.0K |
| Jun 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $96.7K |
| May 29, 2026 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Option exercise | 12,825 | $248.0K |
| May 29, 2026 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Option exercise | 3,392 | $67.9K |
| May 29, 2026 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Sale | 16,217 | $687.0K |
| May 21, 2026 | MCKEON BRIAN P Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | MCKEON BRIAN P Director | Option exercise | 6,142 | — |
| May 21, 2026 | Lurker Nancy Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | snyderman nancy lynn MD Director | Option exercise | 6,142 | — |
| May 21, 2026 | Lurker Nancy Director | Option exercise | 6,142 | — |
| May 21, 2026 | LAURENCIN CATO T Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | GAYNOR RICHARD Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | LAURENCIN CATO T Director | Option exercise | 6,142 | — |
| May 21, 2026 | GAYNOR RICHARD Director | Option exercise | 6,142 | — |
| May 21, 2026 | snyderman nancy lynn MD Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | Cooke Shane Director | Tax withheld | 3,207 | $118.5K |
| May 21, 2026 | Wright Christopher I Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | Cooke Shane Director | Option exercise | 6,142 | — |
| May 21, 2026 | Wright Christopher I Director | Option exercise | 6,142 | — |
| May 21, 2026 | Wilson Frank Anders Director | Tax withheld | 1,475 | $54.5K |
| May 21, 2026 | Wilson Frank Anders Director | Option exercise | 6,142 | — |
| May 4, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $67.5K |
| May 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 9,000 | $300.6K |
| May 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $96.7K |
| Apr 11, 2026 | Lurker Nancy Director | Option exercise | 3,751 | — |
| Apr 11, 2026 | Lurker Nancy Director | Tax withheld | 901 | $30.1K |
| Apr 6, 2026 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 plan | 2,034 | $70.3K |
| Apr 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 plan | 9,000 | $319.6K |
| Apr 1, 2026 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 plan | 5,000 | $96.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Alkermes plc.
Free account. Everything above stays public.
Write why you follow Alkermes plc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading